Literature DB >> 16443243

Hepatitis C virus genotypes in southern Taiwan: prevalence and clinical implications.

Chuan-Mo Lee1, Sheng-Nan Lu, Chao-Hung Hung, Wei-Chih Tung, Jing-Houng Wang, Hung-Da Tung, Chien-Hung Chen, Tsung-Hui Hu, Chi-Sin Changchien, Wei-Jen Chen.   

Abstract

The role of hepatitis C virus (HCV) genotypes in the development of hepatocellular carcinoma (HCC) is still controversial. To determine the distribution and clinical implications of HCV genotypes in southern Taiwan, we analysed 418 patients with chronic HCV infections. HCV genotypes were determined using an HCV Line Probe Assay. The predominant HCV genotype was 1b (45.5%), followed by 2a/2c (30.9%) and 2b (6.9%). The prevalence of genotype 1b in HCC patients (60.3%) was significantly higher than in those with liver cirrhosis (38.7%) and chronic hepatitis (38.7%) (P=0.003 and P<0.001, respectively). Patients with chronic HCV 2a/2c infection had higher alanine aminotransferase (ALT) levels than those with chronic HCV 1b infection (P<0.001). Univariate analysis revealed that disease severity was significantly correlated with older age, genotype 1b, lower ALT levels and lower viral load. Based on multiple logistic regression analysis, after adjusting for age and serum HCV RNA levels, HCV 1b infection was still a significant risk factor for HCC. In conclusion, the predominant genotypes in southern Taiwan were 1b and 2a/2c, and disease severity was associated with genotype 1b.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16443243     DOI: 10.1016/j.trstmh.2005.10.008

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  13 in total

1.  Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3.

Authors:  Samir R Shah; Keyur Patel; Patrick Marcellin; Graham R Foster; Michael Manns; Shyam Kottilil; Letha Healey; Erik Pulkstenis; G Mani Subramanian; John G McHutchison; Mark S Sulkowski; Stefan Zeuzem; David R Nelson
Journal:  Clin Gastroenterol Hepatol       Date:  2011-05-13       Impact factor: 11.382

2.  Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.

Authors:  David R Nelson; Yves Benhamou; Wan-Long Chuang; Eric J Lawitz; Maribel Rodriguez-Torres; Robert Flisiak; Jens W F Rasenack; Wiesław Kryczka; Chuan-Mo Lee; Vincent G Bain; Stephen Pianko; Keyur Patel; Patrick W Cronin; Erik Pulkstenis; G Mani Subramanian; John G McHutchison
Journal:  Gastroenterology       Date:  2010-07-01       Impact factor: 22.682

3.  Genetic variation of hepatitis C virus in a cohort of injection heroin users in Wuhan, China.

Authors:  Jin-Song Peng; Xu Wang; Man-Qing Liu; Dun-Jin Zhou; Jie Gong; Han-Ming Xu; Jian-Ping Chen; Hong-Hao Zhu; Wang Zhou; Wen-Zhe Ho
Journal:  Virus Res       Date:  2008-03-18       Impact factor: 3.303

4.  Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy.

Authors:  Hsien-Hong Lin; Shih-Jer Hsu; Sheng-Nan Lu; Wan-Long Chuang; Chao-Wei Hsu; Rong-Nan Chien; Sien-Sing Yang; Wei-Wen Su; Jaw-Ching Wu; Tzong-Hsi Lee; Cheng-Yuan Peng; Kuan-Chiao Tseng; Albert Qin; Yi-Wen Huang; Pei-Jer Chen
Journal:  JGH Open       Date:  2021-07-10

5.  Analysis of Extrahepatic Multiple Primary Malignancies in Patients with Hepatocellular Carcinoma according to Viral Infection Status.

Authors:  Keita Kai; Atsushi Miyoshi; Kenji Kitahara; Masanori Masuda; Yukari Takase; Kohji Miyazaki; Hirokazu Noshiro; Osamu Tokunaga
Journal:  Int J Hepatol       Date:  2012-12-01

6.  Predictors for Early Identification of Hepatitis C Virus Infection.

Authors:  Mei-Hua Tsai; Kuei-Hsiang Lin; Kuan-Tsou Lin; Chi-Ming Hung; Hung-Shiang Cheng; Yu-Chang Tyan; Hui-Wen Huang; Bintou Sanno-Duanda; Ming-Hui Yang; Shyng-Shiou Yuan; Pei-Yu Chu
Journal:  Biomed Res Int       Date:  2015-08-27       Impact factor: 3.411

7.  Hepatitis C virus infection among injection drug users with and without human immunodeficiency virus co-infection.

Authors:  Meng-Hsuan Hsieh; Jih-Jin Tsai; Ming-Yen Hsieh; Chung-Feng Huang; Ming-Lun Yeh; Jeng-Fu Yang; Ko Chang; Wei-Ru Lin; Chun-Yu Lin; Tun-Chieh Chen; Jee-Fu Huang; Chia-Yen Dai; Ming-Lung Yu; Wan-Long Chuang
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

8.  Translational research of telecare for the treatment of hepatitis C.

Authors:  Wan-Lin Chen; Wen-Ta Chiu; Ming-Shun Wu; Mei-Huang Hsu; Shin-Han Tsai
Journal:  Biomed Res Int       Date:  2014-06-10       Impact factor: 3.411

9.  Peripheral blood toll-like receptor 4 correlates with rapid virological response to pegylated-interferon and ribavirin therapy in hepatitis C genotype 1 patients.

Authors:  Chuan-Mo Lee; Tsung-Hui Hu; Sheng-Nan Lu; Jing-Houng Wang; Chao-Hung Hung; Chien-Hung Chen; Yi-Hao Yen
Journal:  BMC Gastroenterol       Date:  2016-07-25       Impact factor: 3.067

10.  Genotype distribution and treatment response among incarcerated drug-dependent patients with chronic hepatitis C infection.

Authors:  Chun-Han Cheng; Ching-Chung Lin; Huan-Lin Chen; I-Tsung Lin; Chia-Hsien Wu; Yuan-Kai Lee; Ming-Jong Bair
Journal:  PLoS One       Date:  2018-02-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.